PHASE I/II ANTIVIRAL ACTIVITY OF 9R2, PROPYLADENINE (PMPA) IN HIV INFECTION

9R2 丙腺嘌呤 (PMPA) 在 HIV 感染中的 I/II 期抗病毒活性

• 批准号: 6297522
• 负责人: PATRICIA A BARDITCH-CROVO
• 金额: $ 0.23万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6297522
• 关键词: AIDS therapy; HIV infections; adenine analog; antiviral agents; clinical research; clinical trial phase I; drug screening /evaluation; human subject; human therapy evaluation

All evaluations have been completed for the study. A single infusion of PMPA resulted in a median 0.2 log of 0.4 log decline in plasma HIV-RNA at day 7 in the 1 mg/kg or 3 mg/kg groups respectively. PMPA appears to be a potent anti-HIV in humans. A single dose of PMPA had a sustained anti-viral effect. The rebound of viral RNA levels after discontinuation of PMPA is delayed.

研究的所有评价均已完成。单次输注 PMPA导致血浆HIV-RNA中位值下降0.2 log或0.4 log 在第7天，1 mg/kg或3 mg/kg组分别。PMPA似乎 在人体内是一种有效的抗艾滋病毒药物。单剂量的PMPA具有持续的 抗病毒作用。停药后病毒RNA水平的反弹 PMPA延迟了。